COMP <GO>
MAIA vs CING // RSI-14 & 200D SMA MOMENTUM
MAIA Biotechnology Inc. (NYSE) VS. Cingulate Inc. (NASDAQ) • 15-METRIC TALLY: MAIA 1
— CING 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CING
LAST: $1.10 (-6.78%) • MKT CAP: $72.9M
rsi-technicals
45.2
LAST: $4.98 (-4.05%) • MKT CAP: $75.5M
rsi-technicals
51.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAIA VS. CING)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MAIA | CING | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -23.06% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | MAIA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.2 | 51.6 | -6.47 | CING | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $72.9M | $75.5M | -$2.6M | CING | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MAIA REV | CING REV | MAIA GROSS % | CING GROSS % | MAIA FCF | CING FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$18.8M | -$17.4M |
| FY 2024 | $0 | $0 | — | — | -$15.7M | -$18.7M |
| FY 2023 | — | $0 | — | — | — | -$15.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAIA // BETA —
CING // BETA —